David Gómez‐Almaguer

article 2017

Danazol as First-Line Therapy for Myelodysplastic Syndrome

·doi:10.1016/j.clml.2017.11.007

BackgroundAllogeneic stem cell transplantation (ASCT) represents the only option with a potential cure rate of 30% to 50% in myelodysplastic syndrome (MDS); however, < 5% of patients are optimal candidates for this management. Therapeutic o…

article 2016

Danazol As First-Line Therapy for Myelodysplastic Syndromes

·doi:10.1182/blood.v128.22.5528.5528

Abstract Introduction: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological disorders characterized by ineffective hematopoiesis and variable degrees of peripheral cytopenias. Neither curative nor standard thera…

article 2011

Danazol as first-line therapy for aplastic anemia

·doi:10.1007/s00277-011-1163-x

Immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) plus cyclosporine A (CsA) is the standard treatment for aplastic anemia (AA) patients not eligible for allogeneic hematopoietic stem cell transplantation (HSCT). In the abse…